dr. william gradishar on the standard duration of tamoxifen
Published 11 years ago • 193 plays • Length 2:25Download video MP4
Download video MP3
Similar videos
-
2:57
dr. gradishar comments on the treatment of early stage breast cancer with endocrine therapy
-
2:21
dr. gradishar discusses advances in the treatment of her2-positive breast cancer
-
1:02
dr. gradishar discusses the results of the bolero-1 trial
-
1:59
william j. gradishar, md
-
7:46
san antonio roundtable, part 1: fulvestrant dose and tamoxifen duration
-
1:57:47
drs. hamilton, gradishar, rugo, & schmid discuss #breastcancer at #sabcs22 - http://bit.ly/3zedpm8
-
1:05
dr. o’regan on the mechanism of action of trastuzumab
-
1:38
dr. brufsky on the results of a study of trastuzumab and eribulin for her2 mbc
-
11:53
adjuvant treatment, her2 positive & targeted therapies
-
2:21
dr. swain on the next steps for pertuzumab in breast cancer
-
2:49
2012 sabcs - should patients take 10 years of tamoxifen after breast cancer?
-
0:18
copy of dr. goetz on treatment of metastatic hr breast cancer
-
45:21
cancer connections - survivorship panel: what to expect years later
-
30:22
adjuvant therapy | 2023 ku breast cancer year in review conference
-
3:31
innovative techniques for radiation oncology
-
1:59
dr. levy on the role of chemotherapy in the treatment of lung cancer
-
20:13
advanced hormone receptor-positive breast cancer
-
34:38
sabcs 2013: triple-negative therapy and chemotherapy
-
9:19
treatment of her2 metastatic breast cancer